Lenka Kyrych Sadilkova, Ph.D. from SOTIO speaks about the AACR 2021 Poster: SOTIO Demonstrates Strong Potential of SOT102 (ADC Targeting Claudin 18.2) for Treatment of Solid Tumors in Preclinical Studies.
In a virtual poster presentation at the 2021 American Association of Cancer Research (AACR) Annual Meeting, SOTIO, a clinical-stage immuno-oncology firm owned by PPF Group, revealed new preclinical results of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors. The findings, which show that SOT102 has a high propensity for eradicating CLDN18.2-expressing tumor cells in a target-specific manner, serve as proof of concept for both SOT102 and SOTIO’s patented ADC platform.
The following are some of the main findings from the poster "SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with good therapeutic potential in solid tumors expressing low target levels":
SOT102 demonstrated high CLDN18.2 specificity and binding affinity, as well as effective tumor cell killing in vivo.
Independent of CLDN18.2 expression levels, complete responses were found in all ten patient-derived mouse xenograft models, including those for gastric, pancreatic, liver, colon, and lung adenocarcinomas.
SOT102 showed good tolerability and pharmacokinetic properties, with reported half-lives of eight and thirteen days in cynomolgus monkeys and rats, respectively.
SOT102 has been shown to be stable in vitro and in vivo with no major payload loss.
SOT102 is a CLDN18.2 targeting antibody-drug conjugate being developed in partnership with NBE-Therapeutics. It is based on a patented, highly selective monoclonal antibody conjugated to a potent cytotoxic drug molecule. SOT102 is currently undergoing IND-enabling trials, with an IND filing scheduled for the fourth quarter of 2021 and a first-in-human clinical trial in patients with gastric and pancreatic cancer scheduled for the first half of 2022.
A copy of the poster can be accessed below.
Link to Poster:
https://sotio.com/storage/files/35/AACR-2021-poster-SOT102.pdf